The FDA on November 30, 2021, approved DARZALEX Faspro® and KYPROLIS® (Carfilzomib) plus Dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy. DARZALEX Faspro® is a product of Janssen Biotech, Inc.
Bottom Ad
Advertisement
Subscribe
